-
Hinova Pharmaceuticals’ HC-1119 NDA Accepted for Review by NMPA
•
Chengdu-based biotech Hinova Pharmaceuticals Inc. (SHA: 688302) has announced that the New Drug Application (NDA) filing for its Category 1 drug HC-1119 has been accepted for review by the National Medical Products Administration (NMPA). The intended indication is for patients with metastatic castrate-resistant prostate cancer (mCRPC) who have failed to…
-
Boehringer Ingelheim Initiates Phase III FIBRONEER Studies for PDE4B Inhibitor BI 1015550
•
German pharmaceutical giant Boehringer Ingelheim (BI) has announced the first patient enrollments in the Phase III FIBRONEER studies for its phosphodiesterase 4b (PDE4B) inhibitor, BI 1015550. The studies are focused on idiopathic pulmonary fibrosis (IPF) and progressive fibrosis interstitial lung disease (PF-ILD), two conditions with limited treatment options. Global Study…
-
Grand Pharmaceutical Group Reports 15.1% Revenue Growth in 2022 Financials
•
China-based Grand Pharmaceutical Group Limited (HKG: 0512) published its 2022 financials, reporting revenues of HKD 9.562 billion (USD 1.2 billion) over the 12 months, marking a 15.1% increase year-on-year (YOY). The net profit attributable to equity holders reached HKD 2.14 billion (USD 272 million), up 15.4% YOY. The company invested…
-
Ascentage Pharma’s 2022 Revenue Soars with Olverembatinib Sales
•
China-based Ascentage Pharma (HKG: 6855) has announced its 2022 financial results, marking the first year of commercial sales for olverembatinib (HQP1351). The third-generation BCR-ABL-targeted tyrosine kinase inhibitor (TKI) was approved in November 2021 to treat TKI-resistant chronic-phase CML (CML-CP) or accelerated-phase CML (CML-AP) with the T315I mutation. The company recorded…
-
Ping An Good Doctor Reports Revenue Decline but Medical Services Growth in 2022
•
China-based Ping An Healthcare and Technology Co., Ltd (HKG: 1833), also known as Ping An Good Doctor, released its 2022 financial report. The company recorded revenues of RMB 6.16 billion (USD 902.9 million) throughout the year, marking a 16.01% decrease year-on-year (YOY). Losses narrowed to RMB 611 million (USD 89.5…
-
JD Healthcare Reports 52.3% Revenue Growth in 2022 Financial Report
•
JD Healthcare, a unit of China’s e-commerce giant JD.com (NASDAQ: JD), released its 2022 financial report, showing total revenues of RMB 46.7 billion (USD 6.84 billion), a 52.3% increase year-on-year (YOY). As of December 31, 2022, the platform had more than 154 million annual active users, with healthcare daily inquiries…
-
WuXi Biologics Reports 48.4% Revenue Growth in 2022 Financial Report
•
China-based WuXi Biologics (HKG: 2269) released its 2022 financial report for the period ending December 31, 2022. The Contract Development and Manufacturing Organization (CDMO) reported total income of RMB 15.27 billion (USD 2.237 billion), marking a 48.4% increase year-on-year (YOY). Net profits also rose by 47.1% YOY, reaching RMB 5.05…
-
Advenchen Lab’s AL8326 and Hengrui’s SHR-A1811 Receive Breakthrough Therapy Designations
•
The Center for Drug Evaluation (CDE) website indicates that Advenchen Lab’s AL8326 and Hengrui Pharmaceuticals’ (SHA: 600276) SHR-A1811 have been awarded separate breakthrough therapy designations (BTDs). This recognition highlights the potential of both drugs to significantly improve the treatment of cancer patients. Advenchen’s AL8326: A Promising TKI InhibitorAdvenchen’s drug candidate…
